Business Wire (Thu, 8:30AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,661 people get ACTC.OB articles and Market Currents by email alert.
Get email alerts on ACTC.OB »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Business Wire (May 9, 2013)
-
-
-
Business Wire (Apr 23, 2013)
-
-
Business Wire (Apr 16, 2013)
-
Business Wire (Apr 15, 2013)
-
-
-
-
-
Business Wire (Mar 12, 2013)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Earnings Preview: Pluristem TherapeuticsVytautas Drumelis • Tue, Jun 19, 2012
-
Business Wire (Thu, 8:30AM)
-
Business Wire (May 9, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Apr 16, 2013)
-
Business Wire (Apr 15, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Mar 8, 2013)
-
Business Wire (Mar 7, 2013)
-
Business Wire (Mar 4, 2013)
ACTC.OB vs. ETF Alternatives
Company Description
Currently, there's no company description for ACTC.OB.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, March 14, 8:45 AM Advanced Cell Technology (ACTC.OB) receives approval from an independent Data & Safety Monitoring Board to proceed with the next stage of three stem cell studies in the U.S. and Europe in people with the vision disorders Stargardts Macular Dystrophy and dry age-related macular degeneration. The two trials in the U.S. can include patients with better vision than previously allowed. (PR) 4 Comments [Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.